127 related articles for article (PubMed ID: 1746011)
21. Collaborative study on assays of activated FIX (FIXa). On behalf of the factor VIII and factor IX subcommittee of the ISTH. International Society on Thrombosis and Haemostasis.
Gray E; Walker D; Heath A; Barrowcliffe TW
Thromb Haemost; 1996 Dec; 76(6):1114-7. PubMed ID: 8972040
[TBL] [Abstract][Full Text] [Related]
22. Registry of clinical trials of antithrombotic drugs in cancer. The Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Subcommittee on Hemostasis and Malignancy.
Zacharski LR; Donati MB
Thromb Haemost; 1989 Jun; 61(3):526-8. PubMed ID: 2799765
[No Abstract] [Full Text] [Related]
23. Initial clinical experience with a new pasteurized monoclonal antibody purified factor VIIIC.
Smith KJ; Lusher JM; Cohen AR; Salzman P
Semin Hematol; 1990 Apr; 27(2 Suppl 2):25-9. PubMed ID: 2128855
[TBL] [Abstract][Full Text] [Related]
24. Recombinant factor IX.
White GC; Beebe A; Nielsen B
Thromb Haemost; 1997 Jul; 78(1):261-5. PubMed ID: 9198163
[TBL] [Abstract][Full Text] [Related]
25. Standard nomenclature for factor VIII and von Willebrand factor: a recommendation by the International Committee on Thrombosis and Haemostasis.
Marder VJ; Mannucci PM; Firkin BG; Hoyer LW; Meyer D
Thromb Haemost; 1985 Dec; 54(4):871-2. PubMed ID: 3937278
[No Abstract] [Full Text] [Related]
26. Revision of the protocol recommended for studies of safety from hepatitis of clotting factor concentrates. International Society for Thrombosis and Hemostasis.
Mannucci PM; Colombo M
Thromb Haemost; 1989 Jun; 61(3):532-4. PubMed ID: 2508261
[No Abstract] [Full Text] [Related]
27. Pharmacokinetics and interspecies scaling of recombinant human factor VIII.
Mordenti J; Osaka G; Garcia K; Thomsen K; Licko V; Meng G
Toxicol Appl Pharmacol; 1996 Jan; 136(1):75-8. PubMed ID: 8560482
[TBL] [Abstract][Full Text] [Related]
28. A cross-over pharmacokinetic study of a double viral inactivated factor IX concentrate (15 nm filtration and SD) compared to a SD factor IX concentrate.
Goudemand J; Peynet J; Chambost H; Négrier C; Briquel ME; Claeyssens S; Derlon-Borel A; Guérois C; Caron C; Scherrmann JM; Debray M; Bridey F
Thromb Haemost; 1998 Dec; 80(6):919-24. PubMed ID: 9869161
[TBL] [Abstract][Full Text] [Related]
29. Biochemical and in vivo properties of high purity factor IX concentrates.
Berntorp E; Björkman S; Carlsson M; Lethagen S; Nilsson IM
Thromb Haemost; 1993 Nov; 70(5):768-73. PubMed ID: 8128433
[TBL] [Abstract][Full Text] [Related]
30. A standard nomenclature for factor VIII and factor IX gene mutations and associated amino acid alterations. On behalf of the ISTH SSC Subcommittee on Factor VIII and Factor IX.
Peake I; Tuddenham E
Thromb Haemost; 1994 Sep; 72(3):475-6. PubMed ID: 7855800
[No Abstract] [Full Text] [Related]
31. Registry of multicenter clinical trials. Twelfth and thirteenth report--1990-1991. The Council on Thrombosis and Haemostasis of the International Society and Federation of Cardiology. The Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis.
Boissel JP; Bossard N
Thromb Haemost; 1992 Dec; 68(6):752-78. PubMed ID: 1287891
[No Abstract] [Full Text] [Related]
32. [Comparison of factor VIII:C and factor IX sensitivity of different commercial APTT reagents for canine plasma].
Mischke R
Berl Munch Tierarztl Wochenschr; 1999; 112(10-11):394-9. PubMed ID: 10598358
[TBL] [Abstract][Full Text] [Related]
33. Prophylaxis in children with hemophilia: is it the optimal treatment?
Lusher JM
Thromb Haemost; 1997 Jul; 78(1):726-9. PubMed ID: 9198246
[No Abstract] [Full Text] [Related]
34. Initiation of Pediatric Clinical Trials for Coagulation Factors: Application of Pharmacokinetics and Allometry to First-in-Pediatric Dose Selection.
Mahmood I
J Clin Pharmacol; 2019 Jun; 59(6):829-834. PubMed ID: 30624769
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of recombinant human factor IX: pharmacokinetic studies in the rat and the dog.
Keith JC; Ferranti TJ; Misra B; Frederick T; Rup B; McCarthy K; Faulkner R; Bush L; Schaub RG
Thromb Haemost; 1995 Jan; 73(1):101-5. PubMed ID: 7740479
[TBL] [Abstract][Full Text] [Related]
36. Determination of pharmacokinetics of replacement factor VIII.
Mannucci PM; Morfini M
Semin Hematol; 1990 Apr; 27(2 Suppl 2):8-10. PubMed ID: 2128856
[No Abstract] [Full Text] [Related]
37. Thrombosis in cancer patients treated with hematopoietic growth factors--a meta-analysis. On behalf of the Subcommittee on Haemostasis and Malignancy of the Scientific and Standardization Committee of the ISTH.
Barbui T; Finazzi G; Grassi A; Marchioli R
Thromb Haemost; 1996 Feb; 75(2):368-71. PubMed ID: 8815592
[No Abstract] [Full Text] [Related]
38. Recommendations on the potency labelling of factor VIII and factor IX concentrates.
Hubbard AR; Dodt J; Lee T; Mertens K; Seitz R; Srivastava A; Weinstein M;
J Thromb Haemost; 2013 May; 11(5):988-9. PubMed ID: 23406084
[No Abstract] [Full Text] [Related]
39. Effect of stanozolol on factors VIII and IX and serum aminotransferases in haemophilia.
Greer IA; Greaves M; Madhok R; McLoughlin K; Porter N; Lowe GD; Preston FE; Forbes CD
Thromb Haemost; 1985 Jun; 53(3):386-9. PubMed ID: 3931287
[TBL] [Abstract][Full Text] [Related]
40. [Clinical testing of Premofil M SRK, a blood coagulation factor VIII concentrate purified from human plasma using monoclonal an antibodies].
Perret BA; Poorbeik M; Morell A
Schweiz Med Wochenschr; 1991 Nov; 121(44):1624-7. PubMed ID: 1947960
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
